Pacific Biosciences of California Inc. [PACB] stock Resumed by Cantor Fitzgerald analyst, price target now $31

Pacific Biosciences of California Inc. [NASDAQ: PACB] price surged by 2.68 percent to reach at $0.24. The company report on December 6, 2022 that PacBio and Boston Children’s Hospital Collaborate to Investigate Novel Variants Inaccessible by Short-Read Sequencing.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…

Sponsored

Researchers to Investigate Genetic Variants Associated with Rare Pediatric Diseases.

PacBio, a leading developer of high-quality, highly accurate sequencing solutions, today announced its HiFi sequencing technology will be used in a pilot project for the Children’s Rare Disease Cohorts Initiative (CRDC) at Boston Children’s Hospital. Boston Children’s Hospital researchers will use HiFi whole-genome sequencing (HiFi WGS) for the purpose of investigating genetic and epigenetic variants associated with rare pediatric diseases. Samples from individuals enrolled in multiple rare disease cohorts that have remained undiagnosed after short-read whole exome sequencing will be examined using HiFi WGS. The study will also explore epigenetic variation using the ability of HiFi WGS to measure DNA methylation in every sequencing run.

A sum of 2799036 shares traded at recent session while its average daily volume was at 5.35M shares. Pacific Biosciences of California Inc. shares reached a high of $9.5975 and dropped to a low of $8.86 until finishing in the latest session at $9.19.

The one-year PACB stock forecast points to a potential upside of 25.47. The average equity rating for PACB stock is currently 2.30, trading closer to a bullish pattern in the stock market.

Guru’s Opinion on Pacific Biosciences of California Inc. [PACB]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for PACB shares is $12.33 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on PACB stock is a recommendation set at 2.30. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Cantor Fitzgerald have made an estimate for Pacific Biosciences of California Inc. shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on January 21, 2022. While these analysts kept the previous recommendation, Piper Sandler raised their target price to Neutral. The new note on the price target was released on January 06, 2022, representing the official price target for Pacific Biosciences of California Inc. stock. Previously, the target price had yet another raise to $30, while Cowen analysts kept a Market Perform rating on PACB stock.

The Average True Range (ATR) for Pacific Biosciences of California Inc. is set at 0.85, with the Price to Sales ratio for PACB stock in the period of the last 12 months amounting to 14.34. The Price to Book ratio for the last quarter was 3.31, with the Price to Cash per share for the same quarter was set at 3.90.

PACB Stock Performance Analysis:

Pacific Biosciences of California Inc. [PACB] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -2.55. With this latest performance, PACB shares dropped by -11.63% in over the last four-week period, additionally plugging by 68.32% over the last 6 months – not to mention a drop of -57.39% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for PACB stock in for the last two-week period is set at 48.26, with the RSI for the last a single of trading hit 46.55, and the three-weeks RSI is set at 50.15 for Pacific Biosciences of California Inc. [PACB]. The present Moving Average for the last 50 days of trading for this stock 8.99, while it was recorded at 9.09 for the last single week of trading, and 7.03 for the last 200 days.

Insight into Pacific Biosciences of California Inc. Fundamentals:

Operating Margin for any stock indicates how profitable investing would be, and Pacific Biosciences of California Inc. [PACB] shares currently have an operating margin of -136.51 and a Gross Margin at +45.04. Pacific Biosciences of California Inc.’s Net Margin is presently recorded at -138.85.

Return on Equity for this stock declined to -32.18, with Return on Assets sitting at -14.97.

Pacific Biosciences of California Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 10.70 and a Current Ratio set at 11.20.

PACB Stock EPS

The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for PACB. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Pacific Biosciences of California Inc. go to -1.00%.

Pacific Biosciences of California Inc. [PACB] Insider Position Details

There are presently around $1,965 million, or 88.90% of PACB stock, in the hands of institutional investors. The top three institutional holders of PACB stocks are: ARK INVESTMENT MANAGEMENT LLC with ownership of 28,692,494, which is approximately 2.307% of the company’s market cap and around 0.80% of the total institutional ownership; JACKSON SQUARE PARTNERS, LLC, holding 20,258,099 shares of the stock with an approximate value of $186.17 million in PACB stocks shares; and VANGUARD GROUP INC, currently with $180.69 million in PACB stock with ownership of nearly -7.435% of the company’s market capitalization.

Positions in Pacific Biosciences of California Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 106 institutional holders increased their position in Pacific Biosciences of California Inc. [NASDAQ:PACB] by around 27,498,875 shares. Additionally, 111 investors decreased positions by around 47,313,327 shares, while 51 investors held positions by with 138,971,132 shares. The mentioned changes placed institutional holdings at 213,783,334 shares, according to the latest SEC report filing. PACB stock had 45 new institutional investments in for a total of 18,243,183 shares, while 41 institutional investors sold positions of 7,392,201 shares during the same period.

LEAVE A REPLY

Please enter your comment!
Please enter your name here